Royal Bank of Canada
KROS icon

Royal Bank of Canada’s Keros Therapeutics KROS Stock Holding History

Royal Bank of Canada’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54K Sell
4,867
-811
-14% -$12.5K ﹤0.01% 5456
2025
Q4 		$116K Sell
5,678
-87
-2% -$1.53K ﹤0.01% 5121
2025
Q3 		$91K Sell
5,765
-4,343
-43% -$64.2K ﹤0.01% 5557
2025
Q2 		$135K Buy
10,108
+8,302
+460% +$112K ﹤0.01% 5436
2025
Q1 		$18K Sell
1,806
-9,450
-84% -$110K ﹤0.01% 5958
2024
Q4 		$178K Buy
11,256
+6,530
+138% +$339K ﹤0.01% 4908
2024
Q3 		$274K Buy
4,726
+193
+4% +$9.53K ﹤0.01% 4570
2024
Q2 		$208K Buy
4,533
+2,024
+81% +$109K ﹤0.01% 4737
2024
Q1 		$166K Sell
2,509
-6,418
-72% -$381K ﹤0.01% 4840
2023
Q4 		$355K Buy
8,927
+3,804
+74% +$119K ﹤0.01% 4578
2023
Q3 		$164K Sell
5,123
-12
-0.2% -$448 ﹤0.01% 4981
2023
Q2 		$206K Buy
5,135
+2,743
+115% +$120K ﹤0.01% 4714
2023
Q1 		$102K Sell
2,392
-573
-19% -$28.9K ﹤0.01% 5165
2022
Q4 		$143K Buy
2,965
+2,486
+519% +$116K ﹤0.01% 5174
2022
Q3 		$18K Buy
479
+123
+35% +$4.26K ﹤0.01% 6185
2022
Q2 		$10K Sell
356
-879
-71% -$38.6K ﹤0.01% 6385
2022
Q1 		$67K Sell
1,235
-2,441
-66% -$125K ﹤0.01% 5902
2021
Q4 		$215K Buy
3,676
+2,243
+157% +$112K ﹤0.01% 5269
2021
Q3 		$57K Buy
1,433
+264
+23% +$9.39K ﹤0.01% 6084
2021
Q2 		$49K Sell
1,169
-114
-9% -$6.18K ﹤0.01% 6061
2021
Q1 		$79K Buy
1,283
+837
+188% +$53K ﹤0.01% 5611
2020
Q4 		$31K Buy
446
+345
+342% +$21.7K ﹤0.01% 5863
2020
Q3 		$4K Buy
101
+1
+1% +$40 ﹤0.01% 6178
2020
Q2 		$4K Buy
+100
New +$3.08K ﹤0.01% 6105

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Royal Bank of Canada's KROS Position: Q1 2026 in Review

Royal Bank of Canada reduced its Keros Therapeutics (KROS) stake by 14% in Q1 2026, selling an estimated $12.5K and leaving 4,867 shares worth $54K. The position accounts for ﹤0.01% of the portfolio, ranked #5456.

Royal Bank of Canada first reported a position in KROS in Q2 2020 and has held it in 24 quarters since. The position peaked at $355K in Q4 2023. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Royal Bank of Canada held 4,867 shares of Keros Therapeutics worth $54K as of Q1 2026.
  • Royal Bank of Canada sold 811 Keros Therapeutics shares in Q1 2026, an estimated $12.5K.
  • Keros Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5456 holding.
  • Royal Bank of Canada first reported a position in Keros Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Royal Bank of Canada's Keros Therapeutics position peaked at $355K in Q4 2023.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.